Manufactured Object – Page 23

AstraZeneca Invests $2 Billion in CSPC’s Lipid-Lowering Therapy

11 months ago talkbio0Tagged AstraZeneca, Cardiovascular Diseases, Dosage Forms, GZMH gene, Investments, Lipid-lowering therapy, Lp(a ) disruptor, Pharmaceutical Group

AstraZeneca, CSPC Pharmaceutical Group, lipid-lowering therapy, Lp(a) disruptor, cardiovascular disease, pharmaceutical investment

Kurma Partners Secures €140M for Biofund IV, Aiming for €250M to Fuel European Healthcare Innovation

11 months ago talkbio0Tagged Biofund IV, biotech, Capital, European (ethnic group), Health care facility, healthcare innovation, Investments, Kurma Partners, venture

Kurma Partners, Biofund IV, Healthcare Innovation, Venture Capital, European Biotech, Healthcare Investment

Frazier Replenishes Fund with $630 Million for Public Biotech Investments

11 months ago talkbio0Tagged biotech fund, Biotechnology, Frazier, Investments, public biotechs

Frazier, biotech fund, public biotechs, investment, biotechnology

Johnson & Johnson Invests $2 Billion in New North Carolina Biologics Facility

12 months ago talkbio0Tagged Biological Factors, Facility (object), Investments, Johnson and Johnson, North Carolina, pharmaceutical manufacturing

Johnson & Johnson, North Carolina, Biologics Facility, Pharmaceutical Manufacturing, Investment

Frazier Life Sciences Boosts Evergreen Fund with $630M for Small and Mid-Cap Biotechs

12 months ago talkbio0Tagged Biotechnology, biotechs, Evergreen Fund, Frazier Life Sciences, Health care facility, Mid-Cap, Small

Frazier Life Sciences, Evergreen Fund, Small and Mid-Cap Biotechs, Healthcare Investment, Biotechnology Funding

GE HealthCare’s Flyrcado (flurpiridaz F 18) PET Radiotracer Receives FDA Approval for Enhanced Detection of Coronary Artery Disease

12 months ago talkbio0Tagged Approved, Cardiac imaging, Coronary Arteriosclerosis, F 18, Flyrcado, Health care facility, nuclear cardiology, Pet Animal, Radiotracers, United States Food and Drug Administration

GE HealthCare, Flyrcado, flurpiridaz F 18, PET radiotracer, Coronary artery disease (CAD), FDA approval, Cardiac imaging, Nuclear cardiology

Bristol Myers Squibb Invests $110 Million in T-Cell Therapy Pact with Prime Medicine

12 months ago talkbio0Tagged biotech, BMS, Burning Mouth Syndrome, ex vivo, Investments, Myers, pharmaceutical partnerships, Prime Medicine, squibb, T-cell therapy

Bristol Myers Squibb (BMS), Prime Medicine, T-cell therapy, Ex vivo therapies, Biotech investment, Pharmaceutical partnerships

Aktis Oncology Secures $175M Series B Funding with Backing from Industry Giants

12 months ago talkbio0Tagged Aktis, BMY, Cancer Therapeutic Procedure, CILK1 gene, Drug Industry, Eli Lilly, Investments, Neoplasms, Series B, targeted alpha radiopharmaceuticals

Aktis Oncology, Series B funding, targeted alpha radiopharmaceuticals, cancer treatment, pharmaceutical industry, investment, Lilly, BMY, MRK.

Japanese Regulators Approve Medications from Amgen, Eli Lilly, Takeda, and Nxera

12 months ago talkbio0Tagged amgen, Drug Industry, Eli, Eli Lilly, Japanese language, Nxera, Regulators (device), regulatory, Takeda

Japanese regulators, medication approvals, Amgen, Eli Lilly, Takeda, Nxera, pharmaceutical industry, regulatory updates

AI Guidance for Investors: Navigating the Future with Strategic Approaches and Regulatory Insights

12 months ago talkbio0Tagged Adoption, Advice, Artificial Intelligence, Computer Security, governance, Health care facility, investors, Mapping Strategies, Regulatory Impact, Risk, Strategic AI

AI Guidance for Investors, Strategic AI Adoption, Regulatory Impact on AI, Cybersecurity Risks in AI, AI Mapping Strategies, Data Governance in AI, Future of AI in Healthcare